OYE Therapeutics Secures $5.475 Million Series A Funding for Caffeine-Based Anesthesia Recovery and Overdose Reversal Therapy

OYE Therapeutics, a clinical-stage pharmaceutical company developing a caffeine platform for anesthesia recovery and opioid-induced respiratory depression, announced it raised $5.475 million in a Series A financing on November 28, 2025. The oversubscribed funding round will advance the company's proprietary high-concentration caffeine therapy toward a Phase 1 clinical trial planned for the first quarter of 2026.

The company's investigational therapy represents a novel approach to two significant healthcare challenges: accelerating recovery from anesthesia and deep sedation, and addressing fentanyl-related intoxication through a mechanism distinct from naloxone. This development is particularly important as healthcare systems worldwide grapple with the ongoing opioid crisis and seek more effective tools for managing drug overdoses and post-anesthesia recovery.

OYE Therapeutics' platform is designed to support wakefulness and respiratory drive during recovery from opioid-induced respiratory depression, potentially working alongside existing treatments like naloxone. The company has built its approach on preclinical work and U.S. military grant funding, pursuing applications in both military and civilian acute care settings. WBB Securities LLC, a leading investment management and investment banking firm focused on life sciences, acted as the placement agent for this transaction. More information about the firm is available at https://www.wbbsec.com.

The funding announcement comes at a critical time when healthcare providers are seeking more effective solutions for anesthesia recovery and overdose management. Current approaches to opioid overdose reversal primarily rely on naloxone, which can have limitations in certain situations. OYE Therapeutics' alternative mechanism could provide additional tools for emergency responders and healthcare facilities dealing with opioid-related emergencies.

For anesthesia recovery, the therapy aims to address what the company describes as "accepted-as-intractable" clinical problems, potentially reducing recovery times and improving patient outcomes following surgical procedures. The company's name, OYE, stands for "Open Your Eyes," reflecting both the clinical necessity of their work and their broader vision for healthcare innovation.

The successful Series A financing demonstrates investor confidence in OYE Therapeutics' approach to transforming overlooked clinical challenges into solvable problems. As the company moves toward clinical trials in early 2026, the healthcare industry will be watching closely to see if this caffeine-based platform can deliver on its promise of improving existing treatments through breakthrough enhancements that target serious unmet needs in patient care.